Dr. Patrick Celis, Scientific Administrator from the European Medicines Agency gave a guest lecture on the legal framework for tissue and cell therapies in Europe during a visit to NUI Galway last week to coincide with the Second Annual PurStem Meeting. Dr. Celis has been involved in the implementation of the Regulation on Advanced Therapy Medicinal Products at the European Medicines Agency since 2006.
Over the last ten years, stem cells have shown tremendous potential for the repair and regeneration of a large range of tissues and organs. However, one of the obstacles with translating this potential into clinical therapies is that large numbers of stem cells need to be produced on an industrial scale. PurStem is a project funded under the 7th Framework Programme (FP7) of the European Union and is coordinated by Prof. Frank Barry from Regenerative Medicine Institute (REMEDI), at NUI, Galway. This €3.5m project brings leading researchers in stem cell science and regenerative therapy from across Europe together with small-to-medium enterprises (SME) to develop stem cell manufacturing and test methods to advance the large-scale processing of high quality stem cells in a safe and effective manner.